Commentary: Periocular topotecan for retinoblastoma
- PMID: 30451191
- PMCID: PMC6256899
- DOI: 10.4103/ijo.IJO_1626_18
Commentary: Periocular topotecan for retinoblastoma
Conflict of interest statement
There are no conflicts of interest
Comment on
-
Periocular topotecan for vitreous seeds in retinoblastoma.Indian J Ophthalmol. 2018 Dec;66(12):1833-1838. doi: 10.4103/ijo.IJO_737_18. Indian J Ophthalmol. 2018. PMID: 30451190 Free PMC article.
References
-
- Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80. - PubMed
-
- Wilson TW, Chan HSL, Moselhy GM, Heydt DD, Frey CM, Gallie BL. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol. 1996;114:1390–5. - PubMed
-
- Pascual-Pasto G, Olaciregui NG, Opezzo JAW, Castillo-Ecija H, Cuadrado-Vilanova M, Paco S, et al. Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. J Control Release Off J Control Release Soc. 2017;264:34–44. - PubMed
-
- Shields CL, Douglass AM, Beggache M, Say EAT, Shields JA. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture. Retina Phila Pa. 2016;36:1184–90. - PubMed
-
- Shields CL, Alset AE, Say EAT, Caywood E, Jabbour P, Shields JA. Retinoblastoma control with primary intra-arterial chemotherapy: Outcomes before and during the intravitreal chemotherapy era. J Pediatr Ophthalmol Strabismus. 2016;53:275–84. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
